Referências
Principais artigos
Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003 Mar 4;138(5):424-9.Texto completo Resumo
Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-10. Resumo
Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 Jul 20;189(1):G1-42.Texto completo Resumo
Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009 Jul-Aug;15(suppl 1):1-20.Texto completo Resumo
Expert Panel on Urological Imaging., Mody RN, Remer EM, et al. ACR Appropriateness Criteria® Adrenal Mass Evaluation: 2021 Update. J Am Coll Radiol. 2021 Nov;18(11s):S251-S267.Texto completo Resumo
Artigos de referência
1. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003 Mar 4;138(5):424-9.Texto completo Resumo
2. Agency for Healthcare Research and Quality. Management of clinically inapparent adrenal mass. Feb 2002 [internet publication].Texto completo
3. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552-65. Resumo
4. Aggarwal S, Prete A, Chortis V, et al. Pheochromocytomas most commonly present as adrenal incidentalomas: a large tertiary center experience. J Clin Endocrinol Metab. 2023 Jul 7:dgad401.Texto completo Resumo
5. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-10. Resumo
6. Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015 Apr 17:7:281-93.Texto completo Resumo
7. Nieman LK. Cushing's syndrome. In: Jameson JL, De Groot LJ, eds. Endocrinology. 6th ed. Saunders Elsevier; 2010.
8. Newell-Price J, Bertagna X, Grossman AB, et al. Cushing's syndrome. Lancet. 2006 May 13;367(9522):1605-17. Resumo
9. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 Jul 20;189(1):G1-42.Texto completo Resumo
10. Rowe NE, Kumar RM, Schieda N, et al. Canadian Urological Association guideline: diagnosis, management, and followup of the incidentally discovered adrenal mass. Can Urol Assoc J. 2023 Feb;17(2):12-24.Texto completo
11. Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019 Jul 16;171(2):107-16. Resumo
12. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002 Mar;87(3):998-1003.Texto completo Resumo
13. Dogra P, Sundin A, Juhlin CC, et al. Rare benign adrenal lesions. Eur J Endocrinol. 2023 Apr 5;188(4):407-20.Texto completo Resumo
14. Kawashima A, Sandler CM, Fishman EK, et al. Spectrum of CT findings in nonmalignant disease of the adrenal gland. Radiographics. 1998 Mar-Apr;18(2):393-412. Resumo
15. Herndon J, Nadeau AM, Davidge-Pitts CJ, et al. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018 Dec;62(3):721-8. Resumo
16. Shariq OA, McKenzie TJ. Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment. Ther Adv Chronic Dis. 2021 Jul 20:12:20406223211033103.Texto completo Resumo
17. Tella SH, Kommalapati A, Yaturu S, et al. Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3566-73.Texto completo Resumo
18. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Oct 23;169(6):891-9.Texto completo Resumo
19. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37.Texto completo Resumo
20. Bertherat J, Mosnier-Pudar H, Bertagna X. Adrenal incidentalomas. Curr Opin Oncol. 2002 Jan;14(1):58-63. Resumo
21. Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009 Jul-Aug;15(suppl 1):1-20.Texto completo Resumo
22. Zhou AA, Wu MZ, Pan HJ, et al. A case report of primary adrenal malignant melanoma and literature review. Asian J Surg. 2023 Jul;46(7):3012-3.Texto completo Resumo
23. Xu B, Hong Y, Jin M, et al. Primary adrenal malignant melanoma: a case report and review of literature. Medicine (Baltimore). 2017 Dec;96(51):e8956.Texto completo Resumo
24. Otal P, Escourrou G, Mazerolles C, et al. Imaging features of uncommon adrenal masses with histopathologic correlation. Radiographics. 1999 May-Jun;19(3):569-81. Resumo
25. Expert Panel on Urological Imaging., Mody RN, Remer EM, et al. ACR Appropriateness Criteria® Adrenal Mass Evaluation: 2021 Update. J Am Coll Radiol. 2021 Nov;18(11s):S251-S267.Texto completo Resumo
26. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-75.Texto completo Resumo
27. Reincke M, Fleseriu M. Cushing syndrome: a review. JAMA. 2023 Jul 11;330(2):170-81. Resumo
28. Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons guidelines for adrenalectomy: executive summary. JAMA Surg. 2022 Oct 1;157(10):870-7.Texto completo Resumo
29. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011 Jun;164(6):851-70.Texto completo Resumo
30. Platzek I, Sieron D, Plodeck V, et al. Chemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis. Eur Radiol. 2019 Feb;29(2):806-17. Resumo
31. Di Martino M, García Sanz I, Muñoz de Nova JL, et al. NP-59 test for preoperative localization of primary hyperaldosteronism. Langenbecks Arch Surg. 2017 Mar;402(2):303-8. Resumo
32. Chen Z, Xue Q, Yao S. Nuclear medicine application of pentixafor/pentixather targeting CXCR4 for imaging and therapy in related disease. Mini Rev Med Chem. 2023;23(7):787-803. Resumo
33. Jacobson AF, Deng H, Lombard J, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010 Jun;95(6):2596-606.Texto completo Resumo
34. Pandit-Taskar N, Zanzonico P, Staton KD, et al. Biodistribution and dosimetry of (18)F-Meta-Fluorobenzylguanidine: a first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018 Jan;59(1):147-53.Texto completo Resumo
35. Wong KK, Else T, Viglianti BL, et al. PET imaging of metastatic paraganglioma using novel 3-[(18)F]fluoro-para-hydroxyphenethylguanidine (3-[(18)F]pHPG) radiotracer. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2098-9. Resumo
36. Shahrokhi P, Emami-Ardekani A, Harsini S, et al. (68)Ga-DOTATATE PET/CT compared with (131)I-MIBG SPECT/CT in the evaluation of neural crest tumors. Asia Ocean J Nucl Med Biol. 2020 Winter;8(1):8-17.Texto completo Resumo
37. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006 Jul;36(3):212-27. Resumo
38. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011 Apr;259(1):117-26.Texto completo Resumo
39. Wong KK, Arabi M, Bou-Assaly W, et al. Evaluation of incidentally discovered adrenal masses with PET and PET/CT. Eur J Radiol. 2012 Mar;81(3):441-50. Resumo
40. Libè R, Dall'Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002 Oct;147(4):489-94.Texto completo Resumo
41. Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol. 2009 Jan;160(1):87-92. Resumo
42. Pivonello R, De Martino MC, Colao A. How should patients with adrenal incidentalomas be followed up? Lancet Diabetes Endocrinol. 2014 May;2(5):352-4.
43. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553-8.Texto completo Resumo
44. Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999 Jul;212(1):35-41. Resumo
45. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology. 2002 Feb;222(2):507-12. Resumo
46. Gopan T, Remer E, Hamrahian AH. Evaluating and managing adrenal incidentalomas. Cleve Clin J Med. 2006 Jun;73(6):561-8. Resumo
47. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005 Jan;90(1):72-8.Texto completo Resumo
48. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001 Dec;42(12):1795-9.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal